^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19/CD22 chimeric antigen receptor T cell

    i
    Other names: CD19/CD22 chimeric antigen receptor T cell
    Associations

    News

    Trials
    Company:
    Kecellitics Biotech
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    2years
    Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Kecellitics Biotech Company Ltd
    New P1/2 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 expression
    |
    cyclophosphamide • CD19/CD22 chimeric antigen receptor T cell